Patents by Inventor Christian Stegmann
Christian Stegmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240009026Abstract: The invention relates to a device for use in the thermal therapy treatment of a selected region of the body of a human or of an animal, in particular for use in the treatment of tissue damage after surgical interventions, of injuries, of inflammations and of chronic diseases of the rheumatic type, and in particular for assisting chemotherapeutic treatments, comprising a temperature control device which is provided in order to control a temperature of a temperature control fluid, and a heat transfer device which is arranged to transfer heat to the selected region of the body, wherein the temperature control device is connected, in a fluid conducting manner, to the heat transfer device, and is further arranged to temper the heat transfer device with a heat transferring temperature control fluid flowing through the heat transfer device, and with a control device which is connected to the temperature control device and to the heat transfer device, wherein the control device is arranged to control the temperatureType: ApplicationFiled: November 11, 2021Publication date: January 11, 2024Inventor: Christian STEGMANN
-
Publication number: 20230174508Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: July 20, 2022Publication date: June 8, 2023Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Publication number: 20220388982Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: July 20, 2022Publication date: December 8, 2022Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Publication number: 20220251660Abstract: Provided herein are methods for diagnosing cardiomyopathy by evaluating a sample from a subject for the presence of a population of activated fibroblasts comprising a particular genetic signature (e.g., a genetic signature comprised of differential expression of one or more gene products relative to a normal subject or a population of normal subjects). The one or more gene products may include POSTN, COL22A1, and/or THBS4. Also provided herein are methods for treating cardiomyopathy and for modulating the activity of one or more gene products associated with activation of cardiac fibroblasts in a subject using an agent. Compositions comprising an agent for treating cardiomyopathy and kits for diagnosing cardiomyopathy are also provided by the present disclosure.Type: ApplicationFiled: February 11, 2022Publication date: August 11, 2022Inventors: Patrick T. Ellinor, Mark Chaffin, Amer-Denis Akkad, Christian Stegmann, Irinna Papangeli
-
Publication number: 20220241261Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.Type: ApplicationFiled: December 7, 2021Publication date: August 4, 2022Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS
-
Publication number: 20220142814Abstract: The invention relates to a device for use in the thermal therapy treatment of a selected region of the body of a human or of an animal, in particular for use in the treatment of tissue damage after surgical interventions, of injuries, of inflammations and of chronic diseases of the rheumatic type, and in particular for assisting chemotherapeutic treatments, comprising a temperature control device which is provided in order to control a temperature of a temperature control fluid, and a heat transfer device which is arranged to transfer heat to the selected region of the body, wherein the temperature control device is connected, in a fluid conducting manner, to the heat transfer device, and is further arranged to temper the heat transfer device with a heat transferring temperature control fluid flowing through the heat transfer device, and with a control device which is connected to the temperature control device and to the heat transfer device, wherein the control device is arranged to control the temperatureType: ApplicationFiled: July 1, 2021Publication date: May 12, 2022Inventor: Christian STEGMANN
-
Patent number: 11042517Abstract: Disclosed herein are system, method, and computer program product embodiments for performing a database migration with reduced downtime. Embodiments provide for migrating a source database table at a source database system to a target database table at a target database system. The embodiments provide for configuring the source database system to log changes to the source database table to a log, wherein the log is configured to replay the changes to the target database table and creating a replacement view table at the target database system, wherein the replacement view table provides access to current data from the source database table and the target database table. This approach allows access to the current data as replication continues without the need to take down access to the database.Type: GrantFiled: June 7, 2019Date of Patent: June 22, 2021Assignee: SAP SEInventor: Christian Stegmann
-
Publication number: 20210053941Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: September 1, 2020Publication date: February 25, 2021Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Publication number: 20200387514Abstract: Disclosed herein are system, method, and computer program product embodiments for performing a database migration with reduced downtime. Embodiments provide for migrating a source database table at a source database system to a target database table at a target database system. The embodiments provide for configuring the source database system to log changes to the source database table to a log, wherein the log is configured to replay the changes to the target database table and creating a replacement view table at the target database system, wherein the replacement view table provides access to current data from the source database table and the target database table. This approach allows access to the current data as replication continues without the need to take down access to the database.Type: ApplicationFiled: June 7, 2019Publication date: December 10, 2020Inventor: Christian STEGMANN
-
Patent number: 10793545Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: April 5, 2019Date of Patent: October 6, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
-
Patent number: 10717749Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: September 26, 2016Date of Patent: July 21, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
-
Patent number: 10668071Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: August 10, 2018Date of Patent: June 2, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho-Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20190388410Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.Type: ApplicationFiled: May 31, 2019Publication date: December 26, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS
-
Publication number: 20190233395Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: April 5, 2019Publication date: August 1, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Alexandra RAUSCH, Christian FRIEDRICH, Peter HAUFF
-
Patent number: 10308634Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: November 25, 2015Date of Patent: June 4, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Reinhard Nubbemeyer, Ulf Bömer, Judith Günther, Holger Steuber, Martin Lange, Christian Stegmann, Andreas Sutter, Alexandra Rausch, Christian Friedrich, Peter Hauff
-
Patent number: 10214542Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: September 30, 2016Date of Patent: February 26, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Lücking, Daniel Hog, Jens Geisler, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Gerhard Siemeister, Nicolas Werbeck
-
Publication number: 20180344739Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: ApplicationFiled: August 10, 2018Publication date: December 6, 2018Inventors: Jorma HAßFELD, Tom KINZEL, Johannes KÖBBERLING, Yolanda CANCHO-GRANDE, Kristin BEYER, Susanne RÖHRIG, Maria KÖLLNBERGER, Michael SPERZEL, Nils BURKHARDT, Karl-Heinz SCHLEMMER, Christian STEGMANN, Joachim SCHUHMACHER, Matthias WERNER, Manuel ELLERMANN
-
Patent number: 10118930Abstract: The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: October 30, 2015Date of Patent: November 6, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Manuel Ellermann, Gaelle Valot, Yolanda Cancho Grande, Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Kristin Beyer, Susanne Röhrig, Michael Sperzel, Jan Stampfuß, Imke Meyer, Maria Köllnberger, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Jörg Heiermann, Willem Jan Hengeveld
-
Patent number: 10098883Abstract: The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.Type: GrantFiled: January 26, 2017Date of Patent: October 16, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Jorma Haßfeld, Tom Kinzel, Johannes Köbberling, Yolanda Cancho-Grande, Kristin Beyer, Susanne Röhrig, Maria Köllnberger, Michael Sperzel, Nils Burkhardt, Karl-Heinz Schlemmer, Christian Stegmann, Joachim Schuhmacher, Matthias Werner, Manuel Ellermann
-
Publication number: 20180289685Abstract: The present application relates to novel combinations of at least two components, component A and component B: ?component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; ?component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, ?one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.Type: ApplicationFiled: April 29, 2016Publication date: October 11, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS